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Abstract  
PURPOSE: The 21-gene recurrence score (RS) assay predicts response to adjuvant chemotherapy in early stage, hormone 
receptor-positive (HR+), HER2-negative (HER2-) invasive breast cancer, but the role of the assay in guiding selection of 
chemotherapy regimen has not been established. We conducted this study to examine patterns of use of the RS assay for selecting 
chemotherapy regimens across a statewide registry from 2006-2013. 
METHODS: Demographic, pathologic, and treatment data were abstracted from medical records for 16,666 women with breast 
cancer treated at 25 hospital systems across Michigan who were participating in the Michigan Breast Oncology Quality Initiative. We 
examined treatment patterns based on the RS assay test result.  
RESULTS: 25% of node-negative patients who underwent testing with the RS assay and who were treated with chemotherapy 
received an anthracycline-based regimen, compared to 49% of node-negative, chemotherapy-treated patients who had not 
undergone testing with the RS assay.  Of the node-positive patients who underwent testing with the RS assay and who received 
chemotherapy, 31% received an anthracycline-based regimen. In comparison, 71% of node-positive, chemotherapy-treated patients 
who did not undergo testing received an anthracycline. From 2006-2013, there was a statistically significant decrease in the use of 
anthracyclin -containing regimens in both node-negative and node-positive patients.  
CONCLUSIONS: Use of anthracycline-containing chemotherapy regimens in eligible patients varies with use of the RS assay despite 
the lack of evidence supporting the use of the assay to guide regimen selection. Results of ongoing prospective trials should help 
define the role of the RS assay in this setting.  
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Condensed abstract: Use of the 21-gene RS assay was associated with a reduction in treatment with chemotherapy since 2006 in 
those with node-negative and node-positive ER-positive, HER2-negative breast cancer. Use of the RS assay was also associated 
with a reduction in receipt of anthracycline-containing chemotherapy regimens regardless of nodal status. 
 
Keywords: breast cancer, 21-gene recurrence score, chemotherapy, anthracycline, treatment regimen 
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Introduction 
The 21-gene recurrence score (RS) assay is a multi-parameter gene expression profile test originally designed to identify patients 
with hormone receptor-positive (HR+), HER2-negative (HER2-) lymph node-negative breast cancer who are unlikely to benefit from 
the addition of chemotherapy to endocrine therapy.1 Data supporting the use of the RS assay in this patient population for prediction 
of response to chemotherapy were published in 2006.2 Patients with low RS (0-17) did not benefit from the addition of adjuvant 
chemotherapy to endocrine therapy, whereas those with high RS (31-100) benefitted from both chemotherapy and endocrine 
therapy. The benefit of adding chemotherapy for those with intermediate RS (18-30) remains uncertain.3 
As a result of these initial reports, guidelines from multiple organizations including the American Society of Clinical Oncology (ASCO) 
and the National Comprehensive Cancer Network (NCCN) now recommend the use of this assay for making decisions regarding 
whether or not to administer adjuvant chemotherapy to women with HR+, HER2-, lymph node-negative breast cancer.4, 5 Multiple 
studies have demonstrated increased use of the assay over time, with a concomitant decline in the use of adjuvant chemotherapy.6-8 
In addition, a recent analysis of patients with invasive breast cancer with a RS between 0 and 10 treated with endocrine therapy 
alone demonstrated excellent long-term outcomes, with a rate of invasive disease-free survival at 5 years of 93.8% and a rate of 
freedom from recurrence at 5 years of 98.7%.3 
As a result of the high level of evidence supporting the use of the RS assay in patients with lymph node-negative disease, 
subsequent studies have been conducted to determine if the assay would be similarly useful for making decisions regarding use of 
adjuvant chemotherapy in breast cancer patients with lymph node involvement. Retrospective-prospective analyses evaluating the 
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use of the RS assay for this population demonstrated that, although patients with nodal involvement had a higher risk of disease 
recurrence compared to those without, patients whose tumors had a low RS obtained minimal benefit, and those whose tumors had 
high RS obtained substantial benefit from adjuvant chemotherapy.9, 10  A recently reported prospective trial of patients with 1-3 
positive nodes and RS<12 who were treated with endocrine therapy alone demonstrated a 3-year disease free survival of 97.9%.11 
Based on the retrospective-prospective data described above, the Centers for Medicare and Medicaid Services authorized coverage 
for testing tumors from patients with 1-3 involved lymph nodes, and since 2015 the NCCN guidelines have recommended 
consideration of testing of patients with up to 3 involved lymph nodes.12 In contrast, recently updated ASCO guidelines do not 
recommend use for treatment decision-making in this patient population.5 
Since 2006, the Michigan Breast Oncology Quality Initiative (MiBOQI) has prospectively collected data regarding patient and 
pathologic characteristics, diagnostic tests performed, and treatments administered for women with newly diagnosed breast cancer 
at its 25 member hospital systems across the state of Michigan. Using data from this registry, we investigated changes in the pattern 
of use of the RS assay over time in lymph node-negative and -positive patients and associations between RS assay result and 
chemotherapy administration in multiple patient cohorts. Our primary objective was to examine the association between RS assay 
result and selection of anthracycline-containing versus non-anthracycline-containing regimens based on RS assay result. 
Methods 
Analyzed cohort 
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Women with newly diagnosed breast cancer diagnosed between 2006 and 2013 and treated at one of the 25 hospitals participating 
in MiBOQI were included in this analysis. Because the purpose of MiBOQI is to conduct quality initiatives, MiBOQI has been granted 
an exemption by the University of Michigan Institutional Review Board. Demographic, pathologic, and treatment characteristics were 
abstracted from the medical record. Determination of socioeconomic status was estimated based on each patient’s place of 
residence using data from the 2010 United States census. Patients with non-invasive breast cancer, those who were found to have 
distant metastases within 90 days of diagnosis, those treated with neoadjuvant chemotherapy, and those with bilateral breast cancer 
or a prior history of breast cancer were excluded. 
Appropriateness criteria for 21-gene RS assay testing 
Appropriateness for testing with the 21-gene RS assay was based on the NCCN breast cancer guidelines from 2010.5 The NCCN 
concordant cohort was defined as: patients with HR+, HER2- breast cancer measuring more than 1 cm or measuring 6-10 mm in size 
with additional high risk features, including either grade 2 or 3 or evidence of angiolymphatic invasion, with either no evidence of 
nodal metastases or only micrometastatic lymph node involvement. Tumors 5 mm or less and those with tubular or mucinous 
histology were considered inappropriate for testing (non-concordant). 
21-gene RS assay testing for lymph node-positive cohort 
Patients in the analyzed cohort who had HR+, HER2-negative breast cancer and macrometastatic involvement of at least one lymph 
node were included in the analysis of the lymph node-positive cohort. Participants in Steps 1 or 2 of the SWOG S1007 clinical trial, in 
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which enrolled patients’ tumors were tested with the RS assay (Step 1) and then randomized to adjuvant chemotherapy plus 
endocrine therapy versus endocrine therapy alone (Step 2), were excluded from the analysis. 
Statistical Methods 
All data were analyzed using the statistical package R, version 3.2.3. All patient characteristics were summarized as proportions, and 
statistical significance of variation in testing rates by patient characteristics was assessed using univariate and multivariate logistic 
regression.  Statistical significance was defined as a p-value less than 0.05. 
Results 
Use of RS assay results: Node-negative 
Over time, rates of chemotherapy administration to patients with both node-negative and micrometastatic node-positive disease in 
the NCCN concordant cohort decreased, from 39 of 116 patients (34%) and 6 of 6 patients (100%), respectively, in 2006 to 180 of 
1013 (18%) and 25 of 74 (34%), respectively, in 2013 (p<0.001 for both groups, Supplemental Figure 1). Chemotherapy use 
decreased over time in patients with node negative and micrometastatic node-positive disease who underwent testing with the RS 
assay (p<0.001 and p=0.001, respectively), but not in those who were not tested (Figures 1A and 1B). Although the proportion of 
patients treated with chemotherapy decreased overall, receipt of chemotherapy was greater with increasing RS in the node-negative 
cohort (p<0.001, Figures 2A and 3A).  
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Of the 3911 patients in the node-negative cohort who underwent testing with the RS assay from 2006-2013, 923 (24%) were treated 
with chemotherapy. Six percent of patients with a low RS were treated with chemotherapy, compared with 46% of those with an 
intermediate RS and 90% of those with a high RS (p<0.001, Figure 2A). In those with a low RS, receipt of chemotherapy decreased 
from 2006 to 2013 (p<0.001, Supplemental Figure 2). Among the 923 patients, 232 (25%) received an anthracycline-based regimen 
(Figure 2A and Supplemental Figure 3A). In comparison, of the 787 chemotherapy-treated patients in the node-negative cohort who 
did not undergo testing, 49% received an anthracycline-based regimen. From 2006-2013, there was a statistically significant 
decrease in the use of anthracycline-containing regimens (Figure 1A).  
On univariate analysis, anthracycline use in those who were tested with the RS assay and received chemotherapy was associated 
with younger age, earlier year of diagnosis, higher tumor grade, and higher recurrence score (Table 1 and Supplemental Figure 3A). 
There was a trend towards an association with lower socioeconomic status. No associations were identified with race, comorbidity, 
tumor size, or presence of micrometastatic nodal disease.  
Similarly, of those who received chemotherapy and did not undergo testing with the RS assay, anthracycline use was associated with 
younger age and earlier year of diagnosis. In addition, anthracycline use was associated with larger tumor size, but not tumor grade. 
No associations were identified with race, comorbidity, or presence of micrometastatic nodal disease.  
Use of RS assay results: Node-positive 
In patients with HR+, HER2- disease and macrometastatic lymph node involvement, testing with the RS assay was associated with 
decreased treatment with adjuvant chemotherapy compared to no testing (Figure 1C and Supplemental Figure 4). Of the 392 
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patients who underwent testing with the RS assay, 165 (42%) were treated with chemotherapy, and 31% of those patients received 
an anthracycline-based chemotherapy regimen (Supplemental Figures 3B and 4). Chemotherapy use increased with increasing RS 
(Figure 3B). In contrast, of the 1772 chemotherapy-treated patients with HR+, HER2-, node-positive disease who did not undergo 
testing, 71% received an anthracycline-based regimen. From 2006-2013, there was a statistically significant decrease in the use of 
anthracycline-containing regimens in node-positive patients (Figure 1C).    
Examination of the cohort with 1-3 involved lymph nodes revealed that treatment with chemotherapy increased with increasing 
recurrence score, from 34% of those with a low RS, to 49% of those with an intermediate RS, to 96% of those with a high RS (Figure 
2B). In comparison, 79% of patients with HR+, HER2- disease and with 1-3 involved lymph nodes who did not undergo testing with 
the RS assay were treated with chemotherapy. Administration of anthracycline-based chemotherapy regimens in patients with 1-3 
involved lymph nodes increased with increasing RS. Anthracyclines were administered to 23%, 35%, and 36% of patients with a low, 
intermediate, and high RS, respectively (Figure 2B). In contrast, 68% of chemotherapy-treated patients with HR+, HER2- disease 
and 1-3 involved lymph nodes who were not tested with the RS assay received an anthracycline-containing regimen. 
Of those who were tested with the RS assay and received chemotherapy, there were no statistically significant associations between 
anthracyclin  use and age, race, comorbidity, socioeconomic status, year of diagnosis, tumor grade, tumor size, nodal involvement, 
or recurrence score. In contrast, of those who were received chemotherapy and who did not undergo testing with the RS assay, 
anthracycline use was associated with younger age, lower comorbidity, intermediate socioeconomic status, earlier year of diagnosis, 
larger tumor size, and increased nodal involvement. There was a trend towards an association with white race. No associations were 
identified with tumor grade.  
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Rate of testing over time 
Of the 16,666 MiBOQI registry patients included in our analysis, 7124 (42.7%) met the NCCN criteria for testing of patients with 
node-negative or micrometastatic node-positive disease, referred to as the node-negative cohort. Overall, 3911 (54.9%) of patients in 
the node-negative cohort underwent testing, and this rate increased from 43.8% in 2006 to 62.2% in 2013 (Figure 4; p<0.001). 
Corresponding increases over time were from 46% to 63% in patients without involved lymph nodes (n=6623; p<0.001) and from 0% 
to 49% in patients with microscopic nodal metastases (n=501; p<0.001). The percentage of patients in the node-negative cohort 
between 2006 and 2013 who underwent testing at each participating site ranged from 35.4% to 73.3% (Supplemental Figure 5). Of 
the 3911 tumors that were tested, 2383 (60.9%) of RS were in the low range, 1187 (30.4%) in the intermediate range, and 341 
(8.7%) in the high range. 
Of the remaining 9542 patients who did not meet the NCCN criteria for testing, 2671 (28%) had HR+, HER2- breast cancer with 
macrometastatic involvement of at least one lymph node. Rates of testing in this patient cohort increased from 0% in 2006 to 26% in 
2013 (p<0.001, Figure 4). At the 25 participating sites, the percentage of patients tested in 2006-2013 ranged from 4% to 30% 
(Supplemental Figure 5). Of the 392 tumors that were tested, 239 (61.0%) of RS were in the low range, 116 (29.6%) in the 
intermediate range, and 37 (9.4%) in the high range. 
Factors associated with testing with the 21-gene RS assay 
In the node-negative cohort, on univariate analysis, variables associated with receipt of testing included younger age, white race, 
smaller tumor size, lack of lymph node involvement, lower tumor grade, lower comorbidity, and more recent time period 
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(Supplemental Table 1). No association with area-level socioeconomic status was identified. Similar findings were noted on 
multivariate analysis.  
In the cohort of patients with HR+, HER2-, lymph node-positive disease, variables associated with receipt of testing on univariate 
analysis included increased age, smaller tumor size, fewer number of lymph nodes involved, lower tumor grade, and more recent 
time period (Supplemental Table 1). There were no associations noted with race, socioeconomic status, or comorbidity. In 
multivariate analyses the same associations were identified except tumor grade was only borderline significant. 
Discussion 
In hospital systems across Michigan, use of the 21-gene RS assay for determining prognosis and likely benefit from chemotherapy 
for patients with HR+, HER2-, node-negative breast cancer has been increasing since the introduction of the assay a decade ago. 
This increasing use has been associated with a concomitant decline in adjuvant chemotherapy administration, especially in those 
patients with recurrence scores in the low and low-intermediate range. The rates of chemotherapy administration in patients with low 
RS is very low across the state (average of 6% from 2006-2013), and has been decreasing over time. The rates of omission of 
chemotherapy in patients with high RS is higher, approximately 10%. Both of these findings are similar to those previously reported 
in other cohorts, and demonstrate excellent concordance with published guidelines for patients with node-negative disease.13 Our 
findings confirm previously reported findings regarding increasing use of the RS assay over time and concomitant declining use of 
chemotherapy. One large study evaluating the association in the first years (2006-2008) following introduction of the RS assay 
demonstrated that testing was associated with a lower odds of receipt of chemotherapy, with an odds ratio of 0.70 (95% CI 0.62-
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0.80).6 A second study analyzed the association in a Medicare population between 2005-2009 and similarly demonstrated decreased 
use of chemotherapy over time in this older population who underwent testing with the RS assay.7 Our results also extend these 
findings by including a more recent time period, and demonstrate that the reduction in chemotherapy has persisted over almost 10 
years since introduction of the RS assay into routine clinical practice.  
Importantly, we found that use of the RS assay was associated with a shift in the use of chemotherapy regimens from anthracycline-
based regimens to non-anthracycline-based regimens in both the node-negative and node-positive cohorts. This trend was observed 
despite a lack of clinical data to support using the RS assay results for choosing specific adjuvant chemotherapy regimens. However, 
we are unable to determine how much of the decreased use of anthracycline-containing regimens is due to use of the RS assay and 
how much is due to publication of findings from other clinical trials. During the same time period, the US Oncology Research group 
published the results of the docetaxel and cyclophosphamide (TC) versus doxorubicin and cyclophosphamide (AC) clinical trial, 
demonstrating superior disease-free and overall survival with the non-anthracycline-containing regimen.14, 15 Of note, the 
anthracycline-containing comparator arm in that trial did not include a taxane. Subsequent analysis of national patient cohorts 
demonstrated a decline in the use of anthracyclines for breast cancer since 2005.16  
In contrast, recently reported data demonstrate that for patients with nodal involvement, anthracycline-containing regimens are more 
effective than non-anthracycline-containing regimens, although exploratory subset analyses suggested less benefit in patients with 
HR+, HER2- disease.17 Our findings suggest that physicians may be using results of the RS assay to select patients for non-
anthracycline-containing regimens. Alternatively, the observation that use of RS assay is associated with a preference for non-
anthracycline-based chemotherapy regimens could reflect, in part, patient selection. In the node-negative cohort, unfavorable tumor 
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characteristics and younger age were associated with use of an anthracycline regardless of testing with the RS assay. However, in 
the lymph node-positive cohort, similar findings were identified only in the patients who did not undergo testing with the RS assay. 
There has been a substantial increase in testing of patients with HR+, HER2-, node-positive breast cancer over time, which has 
occurred despite a lack of prospective randomized data to support the clinical utility of the RS assay for this purpose. A prospective 
randomized validation study to determine whether chemotherapy can be safely omitted in patients with HR+ and HER2- disease with 
lymph node involvement has completed accrual (SWOG S1007; clinicaltrials.gov NCT01272037), but results are not yet available. In 
our statewide cohort, we found that those patients with 1-3 involved nodes who underwent testing with the RS assay were 
significantly less likely to receive chemotherapy compared to those who did not undergo testing. This likely reflects a bias of ordering 
physicians for the selection of patients that they would prefer to avoid treating with chemotherapy, since those patients who were 
tested were older and had more favorable tumor characteristics. These findings are consistent with a previously published physician 
survey, which reported that physicians were more likely to consider using the RS assay for patients with 1-3 involved lymph nodes 
with smaller tumors, and that testing would lead to reduced recommendation for treatment with chemotherapy.18  
Finally, in our registry, fewer black patients with node-negative breast cancer underwent testing with the RS assay compared to white 
patients, wh reas there were no detectable racial differences in test ordering for those with node-positive breast cancer. This is in 
contrast to a recent publication from the Carolina Breast Cancer Study, in which rates of testing of patients with node-negative 
disease were similar between white and black patients, but black patients with node-positive disease were 46% less likely to undergo 
testing.19 The basis for these differing findings between the two states is unclear but could represent differences in provider practice 
patterns or insurance coverage. 
Page 14 of 41Cancer
57
58
59
60
This article is protected by copyright. All rights reserved.
Ac
c
e
p
t
e
d
 
A
r
t
i
c
l
e
15 
 
Strengths of our study include data derived from a large, prospective registry specifically designed to evaluate patterns of breast 
cancer care at multiple institutions across a single state, in which comprehensive demographic, clinical, and treatment data are 
collected. There is considerable heterogeneity in terms of both practice setting and patient characteristics. However, due to 
limitations in the registry, we are unable to determine reasons why patients did not receive guideline-concordant testing or 
chemotherapy treatment, why specific chemotherapy regimens were selected, or the impact of treatment selection on patient 
outcome. This information is essential for the performance of root cause analyses in order to develop site level interventions to 
improve concordance with guidelines related to RS assay result utilization for treatment decision-making. 
Overall, use of the 21-gene RS assay for management of patients with both lymph node-negative and positive breast cancer has 
increased in MiBOQI since 2006, and this increase has been accompanied by a concomitant decrease in treatment with 
chemotherapy. In particular, results of the RS assay appear to influence chemotherapy regimen selection by physicians, despite the 
lack of evidence supporting this use of the assay. The results of ongoing clinical trials (clincaltrials.gov NCT00310180; 
NCT01272037) should help further define the clinical utility of the 21-gene RS assay in both the lymph node-negative and node-
positive settings for treatment decision-making.  
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Figure Legends  
Figure 1. Percentage of patients with HR+, HER2- breast cancer who received treatment with any chemotherapy, over time, by 21-
gene assay testing (tested: orange; not tested: blue). In addition, percentage of chemotherapy-treated patients who received an 
anthracycline-based regimen, over time, by 21-gene assay testing (tested: green dashed; not tested: red dashed). Rates are given 
for node-negative disease (part A), micrometastatic nodal disease (part B), and macrometastatic nodal disease (part C).    
Figure 2. Percentage of patients with HR+, HER2- breast cancer treated with anthracycline-based (blue), non-anthracycline based 
(red), and no chemotherapy (green) regimens, by recurrence score (<18, 18-30, >30, not tested). (A) Node-negative cohort. (B) 
Patients with 1-3 positive lymph nodes.  
Figure 3. Bubble plot demonstrating receipt of chemotherapy by recurrence score for patients with HR+, HER2- breast cancer. Each 
circle represents average percentage of patients treated with chemotherapy for each RS, and size of each circle represents the 
number of patients with each RS. (A) Node-negative cohort. (B) Node-positive cohort. 
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Table 1. Univariate analyses of associations between patient and tumor characteristics of patients with HR+, HER2-, lymph node-
negative breast cancer and chemotherapy regimen (anthracycline (A) versus non-anthracycline (Non-A)). Patients are divided into 
those tested and not tested with the RS assay. 
 
Node-negative Cohort (pN0, pN1mi) 
No RS Assay 
Node-negative Cohort (pN0, pN1mi) 
RS Assay 
Characteristic 
A Chemo 
N=385 
Non-A Chemo 
N=402 
 p-value 
A Chemo 
N=232 
Non-A Chemo 
N=691 
 p-value 
       
Clinical 
      
Age at diagnosis, years       
<50 193 (50%) 140 (35%) <0.001 90 (39%) 231 (33%) 0.037 
50-69 172 (45%) 212 (53%)  133 (57%) 401 (58%)  
70+ 20 (5%) 50 (12%)  9 (4%) 59 (9%)  
 
      
Race       
Black 53 (14%) 58 (14%) 0.929 29 (13%) 55 (8%) 0.106 
White 306 (79%) 319 (79%)  190 (82%) 600 (87%)  
Other 26 (7%) 25 (6%)  13 (6%) 36 (5%)  
 
      
Charlson Comorbidity 
Index 
      
0 343 (89%) 347 (86%) 0.236 216 (93%) 623 (90%) 0.471 
1 25 (6%) 35 (9%)  13 (6%) 49 (7%)  
2 15 (4%) 13 (3%)  2 (1%) 9 (1%)  
3+ 2 (1%) 7 (2%)  1 (0%) 10 (1%)  
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Table 1 (Continued) 
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Socioeconomic status       
High 114 (30%) 111 (28%) 0.939 71 (31%) 253 (37%) 0.059 
Medium 142 (37%) 143 (36%)  78 (34%) 233 (34%)  
Low 129 (34%) 134 (33%)  83 (36%) 190 (27%)  
Missing 0 (0%) 14 (3%)  0 (0%) 15 (2%)  
 
      
Year of Diagnosis       
2006-2007 120 (31%) 41 (10%) <0.001 41 (18%) 42 (6%) <0.001 
2008-2011 162 (42%) 204 (51%)  97 (42%) 300 (43%)  
2012-2014 103 (27%) 157 (39%)  94 (41%) 349 (51%)  
 
      
Tumor       
Tumor Size       
pT1 161 (42%) 215 (53%) 0.005 153 (66%) 488 (71%) 0.408 
pT2 199 (52%) 165 (41%)  76 (33%) 195 (28%)  
pT3 25 (6%) 22 (5%)  3 (1%) 8 (1%)  
Other 0 (0%) 0 (0%)  0 (0%) 0 (0%)  
 
      
Nodal Involvement       
pN0 283 (74%) 315 (78%) 0.111 218 (94%) 652 (94%) 0.825 
pN1mi 102 (26%) 87 (22%)  14 (6%) 39 (6%)  
 
      
Tumor Grade       
1 41 (11%) 45 (11%) 0.364 26 (11%) 83 (12%) 0.003 
2 165 (43%) 189 (47%)  101 (44%) 379 (55%)  
3 176 (46%) 163 (41%)  102 (44%) 222 (32%)  
Missing 3 (1%) 5 (1%)  3 (1%) 7 (1%)  
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Table 1 (Continued) 
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RS       
0-17 n/a n/a n/a 30 (13%) 98 (14%) <0.001 
18-30 n/a n/a  100 (43%) 408 (59%)  
31-100 n/a n/a  102 (44%) 185 (27%)  
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Table 2. Univariate analyses of associations between patient and tumor characteristics of patients with HR+, HER2-, lymph node-
positive breast cancer and chemotherapy regimen (anthracycline (A) versus non-anthracycline (Non-A)). Patients are divided into 
those tested and not tested with the RS assay. 
 
HR+, HER2- Lymph Node + Cohort 
No RS Assay 
HR+, HER2- Lymph Node + Cohort 
RS Assay 
Characteristic 
A Chemo 
N=1261 
Non-A Chemo 
N=511 
p-value 
A Chemo 
N=51 
Non-A Chemo 
N=114 
p-value 
       
Clinical 
      
Age at diagnosis, years       
<50 512 (41%) 128 (25%) <0.001 22 (43%) 33 (29%) 0.097 
50-69 674 (53%) 278 (54%)  26 (51%) 64 (56%)  
70+ 75 (6%) 105 (21%)  3 (6%) 17 (15%)  
 
      
Race       
Black 155 (12%) 79 (15%) 0.065 4 (8%) 10 (9%) 0.616 
White 1020 (81%) 408 (80%)  45 (88%) 95 (83%)  
Oth r 86 (7%) 24 (5%)  2 (4%) 9 (8%)  
 
      
Charlson Comorbidity 
Index 
      
0 1134 (90%) 423 (83%) <0.001 48 (94%) 97 (85%) 0.251 
1 80 (6%) 49 (10%)  3 (6%) 9 (8%)  
2 35 (3%) 23 (5%)  0 (0%) 7 (6%)  
3+ 12 (1%) 16 (3%)  0 (0%) 1 (1%)  
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Table 2 (continued) 
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Socioeconomic status       
High 400 (32%) 167 (33%) 0.011 19 (37%) 39 (34%) 0.427 
Medium 436 (35%) 134 (26%)  19 (37%) 34 (30%)  
Low 425 (34%) 191 (37%)  13 (25%) 40 (35%)  
Missing 0 (0%) 19 (4%)  0 (0%) 1 (1%)  
 
      
Year of Diagnosis       
2006-2007 210 (17%) 60 (12%) 0.001 2 (4%) 2 (2%) 0.619 
2008-2011 567 (45%) 212 (41%)  10 (20%) 27 (24%)  
2012-2014 484 (38%) 239 (47%)  39 (76%) 85 (75%)  
 
      
Tumor       
Tumor Size       
pT1 479 (38%) 227 (44%) 0.022 20 (39%) 64 (56%) 0.124 
pT2 614 (49%) 227 (44%)  30 (59%) 49 (43%)  
pT3 149 (12%) 45 (9%)  1 (2%) 1 (1%)  
Other 19 (2%) 12 (2%)  0 (0%) 0 (0%)  
 
      
Nodal Involvement       
pN1 757 (60%) 361 (70%) <0.001 46 (90%) 110 (96%) 0.253 
pN2 350 (28%) 100 (20%)  4 (8%) 3 (3%)  
pN3 154 (12%) 49 (10%)  1 (2%) 1 (1%)  
       
Tumor Grade       
1 204 (16%) 81 (16%) 0.919 11 (22%) 23 (20%) 0.731 
2 688 (55%) 280 (55%)  27 (53%) 66 (58%)  
3 338 (27%) 143 (28%)  13 (25%) 23 (20%)  
Page 24 of 41Cancer
57
58
59
60
This article is protected by copyright. All rights reserved.
Ac
c
e
p
t
e
d
 
A
r
t
i
c
l
e
Table 2 (continued) 
3 
 
Missing 31 (2%) 7 (1%)  0 (0%) 2 (2%)  
       
RS       
0-17 n/a n/a n/a 19 (37%) 57 (50%) 0.296 
18-30 n/a n/a  19 (37%) 36 (32%)  
31-100 n/a n/a  13 (25%) 21 (18%)  
 
 
 
 
 
Page 25 of 41 Cancer
57
58
59
60
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
  
 
 
Figure 1. Percentage of patients with HR+, HER2- breast cancer who received treatment with any 
chemotherapy, over time, by 21-gene assay testing (tested: orange; not tested: blue). In addition, 
percentage of chemotherapy-treated patients who received an anthracycline-based regimen, over time, by 
21-gene assay testing (tested: green dashed; not tested: red dashed). Rates are given for node-negative 
disease (part A), micrometastatic nodal disease (part B), and macrometastatic nodal disease (part C).    
Figure 1A  
177x124mm (300 x 300 DPI)  
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Figure 1. Percentage of patients with HR+, HER2- breast cancer who received treatment with any 
chemotherapy, over time, by 21-gene assay testing (tested: orange; not tested: blue). In addition, 
percentage of chemotherapy-treated patients who received an anthracycline-based regimen, over time, by 
21-gene assay testing (tested: green dashed; not tested: red dashed). Rates are given for node-negative 
disease (part A), micrometastatic nodal disease (part B), and macrometastatic nodal disease (part C).    
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Figure 1. Percentage of patients with HR+, HER2- breast cancer who received treatment with any 
chemotherapy, over time, by 21-gene assay testing (tested: orange; not tested: blue). In addition, 
percentage of chemotherapy-treated patients who received an anthracycline-based regimen, over time, by 
21-gene assay testing (tested: green dashed; not tested: red dashed). Rates are given for node-negative 
disease (part A), micrometastatic nodal disease (part B), and macrometastatic nodal disease (part C).    
Figure 1C  
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Figure 2. Percentage of patients with HR+, HER2- breast cancer treated with anthracycline-based (blue), 
non-anthracycline based (red), and no chemotherapy (green) regimens, by recurrence score (<18, 18-30, 
>30, not tested). (A) Node-negative cohort. (B) Patients with 1-3 positive lymph nodes.  
Figure 2A  
177x124mm (300 x 300 DPI)  
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Figure 2. Percentage of patients with HR+, HER2- breast cancer treated with anthracycline-based (blue), 
non-anthracycline based (red), and no chemotherapy (green) regimens, by recurrence score (<18, 18-30, 
>30, not tested). (A) Node-negative cohort. (B) Patients with 1-3 positive lymph nodes.  
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Figure 3. Bubble plot demonstrating receipt of chemotherapy by recurrence score for patients with HR+, 
HER2- breast cancer. Each circle represents average percentage of patients treated with chemotherapy for 
each RS, and size of each circle represents the number of patients with each RS. (A) Node-negative cohort. 
(B) Node-positive cohort.  
Figure 3A  
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Figure 3. Bubble plot demonstrating receipt of chemotherapy by recurrence score for patients with HR+, 
HER2- breast cancer. Each circle represents average percentage of patients treated with chemotherapy for 
each RS, and size of each circle represents the number of patients with each RS. (A) Node-negative cohort. 
(B) Node-positive cohort.  
Figure 3B  
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Associations between use of the 21-gene Recurrence Score Assay and Chemotherapy Regimen 
Selection in a Statewide Registry  
N Lynn Henry,1 Thomas Braun,2 Haythem Y Ali,3 Khan Munir,1 Samuel M Silver,1 David H Gorski,4,5 Tara M 
Breslin6, Jennifer J Griggs1,2 
 
Supplemental Table  
Supplemental Figures 
Supplemental Figure 1. Percentage of patients with HR+, HER2- breast cancer who were treated with 
chemotherapy, over time. Rates are given for node-negative disease (circles), micrometastatic nodal disease 
(triangles), macrometastatic nodal disease (diamonds), and all cohorts combined (solid line, squares).    
Supplemental Figure 2. Percentage of patients with HR+, HER2-, lymph node-negative breast cancer with 
low recurrence scores who were treated with chemotherapy, over time. 
Supplemental Figure 3A. Bubble plot demonstrating receipt of anthracycline-containing chemotherapy 
(chemo) regimens by recurrence score for chemotherapy-treated patients with HR+, HER2- breast cancer. 
Each circle represents average percentage of patients treated with an anthracycline-based regimen for each 
RS, and size of each circle represents the number of patients with each RS. (A) Node-negative cohort. (B) 
Node-positive cohort. 
Supplemental Figure 4. Percentage of node-positive patients with HR+, HER2- breast cancer treated with 
anthracycline-based (blue), non-anthracycline based (red), and no chemotherapy (green) regimens, by 
recurrence score (<17, 18-30, >30, not tested).  
Supplemental Figure 5. Percentage of patients with HR+, HER2- breast cancer tested with the 21-gene RS 
assay by participating site (designated by letters on the x axis). Rates are given for patients in the NCCN 
concordant cohort (blue) and in the node-positive cohort (red). 
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Supplemental Table 1. Univariate and multivariate analyses of associations between patient and tumor characteristics of patients with HR+, HER2- 
breast cancer and testing with the recurrence score (RS) assay. Patients are divided into the NCCN concordant cohort and the lymph node-positive 
cohort. 
 
NCCN Concordant Cohort (pN0, pN1mi) HR+, HER2- Lymph Node + Cohort 
Characteristic 
RS assay 
N=3911 
No RS assay 
N=3213 
Univariate    
p-value 
Multivariate 
p-value 
RS assay 
N=392 
No RS assay 
N=2279 
Univariate    
p-value 
Multivariate 
p-value 
Clinical 
        
Age at diagnosis, years 
  
<0.0001 <0.0001 
  
0.0008 <0.0001 
<50 1024 (26%) 540 (17%) 
  
87 (22%) 721 (32%) 
  
50-69 2294 (59%) 1258 (39%) 
  
212 (54%) 1096 (48%) 
  
70+ 593 (15%) 1415 (44%) 
  
93 (24%) 462 (20%) 
  
         
Race 
  
0.022 0.002 
  
0.220 0.218 
Black 352(9%) 349 (11%) 
  
40 (10%) 304 (13%) 
  
White 3301 (84%) 2640 (82%) 
  
326 (83%) 1838 (81%) 
  
Other 258 (7%) 224 (7%) 
  
26 (7%) 137 (6%) 
  
         
Charlson Comorbidity 
Index   
<0.0001 <0.0001 
  
0.381 0.014 
0 3439 (88%) 2504 (78%) 
  
326 (83%) 1899 (83%) 
  
1 287 (7%) 424 (13%) 
  
41 (10%) 218 (10%) 
  
2 126 (3%) 174 (5%) 
  
19 (5%) 95 (4%) 
  
3+ 59 (2%) 111 (3%) 
  
6 (2%) 67 (3%) 
  
         
Socioeconomic status 
  
0.077 0.303 
  
0.244 0.546 
High 1307 (33%) 1001 (31%) 
  
129 (32%) 709 (31%) 
  
Medium 1335 (34%) 1099 (34%) 
  
135 (34%) 741 (33%) 
  
Low 1198 (31%) 1050 (33%) 
  
119 (30%) 798 (35%) 
  
Missing 71 (2%) 63 (2%) 
  
9 (2%) 31 (1%) 
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leYear of Diagnosis   <0.0001 <0.0001   <0.0001 <0.0001 2006-2007 233 (6%) 513 (16%)   5 (1%) 333 (15%)   2008-2011 1401 (36%) 1398 (44%)   107 (27%) 968 (42%)   2012-2014 2277 (58%) 1302 (41%) 
  
280 (71%) 978 (43%) 
  
         
Tumor 
        
Tumor Size 
  
<0.0001 <0.0001 
  
<0.0001 0.0003 
pT1 2949 (75%) 2317 (72%) 
  
228 (58%) 923 (41%) 
  
pT2 931 (24%) 810 (25%) 
  
153 (39%) 1063 (47%) 
  
pT3 31 (1%) 86 (3%) 
  
9 (2%) 239 (10%) 
  
Other 0 0 
  
2 (1%) 54 (2%) 
  
         
Nodal Involvement 
  
<0.0001 <0.0001 
  
<0.0001 <0.0001 
pN0 3711 (95%) 2912 (91%) 
  
0 0 
  
pN1mi 200 (5%) 301 (9%) 
  
0 0 
  
pN1 0 0 
  
369 (94%) 1499 (66%) 
  
pN2 0 0 
  
18 (5%) 534 (23%) 
  
pN3 0 0 
  
3 (1%) 244 (11%) 
  
Missing 0 0 
  
2 (1%) 2 (0%) 
  
         
Tumor Grade 
  
0.0001 0.012 
  
<0.0001 0.055 
1 934 (24%) 673 (21%) 
  
113 (29%) 397 (17%) 
  
2 2303 (59%) 1874 (58%) 
  
218 (56%) 1247 (55%) 
  
3 625 (16%) 619 (19%) 
  
55 (14%) 589 (26%) 
  
Missing 49 (1%) 47 (1%) 
  
6 (2%) 46 (2%) 
  
         
Receipt of Chemotherapy 
  
0.172 <0.0001 
  
<0.0001 <0.0001 
No 2835 (72%) 2239 (70%) 
  
210 (54%) 402 (18%) 
  
Yes 923 (24%) 787 (24%) 
  
165 (42%) 1772 (78%) 
  
Missing 153 (4%) 187 (6%) 
  
17 (4%) 105 (5%) 
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Supplemental Figure 1. Percentage of patients with HR+, HER2- breast cancer who were treated with chemotherapy, over time. Rates are given 
for node-negative disease (circles), micrometastatic nodal disease (triangles), macrometastatic nodal disease (diamonds), and all cohorts combined 
(solid line, squares).    
 
 
 
Page 36 of 41Cancer
49
50
51
52
53
54
55
56
57
58
59
60
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
Supplemental Figure 2. Percentage of patients with HR+, HER2-, lymph node-negative breast cancer with low recurrence scores who were treated 
with chemotherapy, over time. 
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Supplemental Figure 3A. Bubble plot demonstrating receipt of anthracycline-containing chemotherapy (chemo) regimens by recurrence score for 
chemotherapy-treated patients with HR+, HER2- breast cancer. Each circle represents average percentage of patients treated with an 
anthracycline-based regimen for each RS, and size of each circle represents the number of patients with each RS. (A) Node-negative cohort. 
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Supplemental Figure 3B. Bubble plot demonstrating receipt of anthracycline-containing chemotherapy (chemo) regimens by recurrence score for 
chemotherapy-treated patients with HR+, HER2- breast cancer. Each circle represents average percentage of patients treated with an 
anthracycline-based regimen for each RS, and size of each circle represents the number of patients with each RS. (B) Node-positive cohort
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Supplemental Figure 4. Percentage of node-positive patients with HR+, HER2- breast cancer treated with anthracycline-based (blue), non-
anthracycline based (red), and no chemotherapy (green) regimens, by recurrence score (<17, 18-30, >30, not tested).  
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Supplemental Figure 5. Percentage of patients with HR+, HER2- breast cancer tested with the 21-gene RS assay by participating site (designated 
by letters on the x axis). Rates are given for patients in the NCCN concordant cohort (blue) and in the node-positive cohort (red). 
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